The renin-angiotensin system is of particular interest to pharmacy students. Again, the renin-angiotensin system has plenty to offer, particularly because converting-enzyme inhibitors and angiotensin receptor antagonists are being used increasingly in the treatment of hypertension and congestive heart failure. The development of orally active renin inhibitors is also an interesting and potentially important area.

The renin-angiotensin system is a hotbed of research, and there is a seemingly endless amount of new information appearing in the literature every day. It is tempting to present some of this in lectures, but I find that most professional students are not interested in new developments unless their clinical relevance is readily apparent. In addition, the renin-angiotensin system is my own area of research, and it is easy to get carried away and lose sight of the forest for the trees. For these reasons, and because of lack of time, I generally steer clear of current research. Nevertheless, the opportunity to discuss new developments often comes up when responding to students’ questions.

Last but not least, the renin-angiotensin system is of interest from the historical point of view. The progression of ideas from the recognition of the relationship between renal disease and hypertension by Bright to the production of experimental renal hypertension by Goldbatt and the discovery of angiotensin by Page (“angiotonin”) and Braun-Menendez (“hypertensin”), culminating in a veritable explosion of research during the past three decades, makes a fascinating story. Once again, however, this does not particularly excite the students, and I generally pass it by.
The following section contains excerpts from my physiology syllabus together with some of my favorite figures to show how I teach this intriguing system.

**PHYSIOLOGY**

Because I generally teach in physiology courses, the physiology of the renin-angiotensin system is the major component of my lectures. I start with an overview of the system by describing the biochemical pathway of angiotensin II formation. My major emphasis here is on the control of renin secretion, because the rate of renin secretion is the primary determinant of the activity of the system, and on the actions of angiotensin II.

**Biosynthesis of Angiotensin II**

The renin-angiotensin system is shown in Fig. 1. The principal steps include enzymatic cleavage of angiotensin I from angiotensinogen by renin, conversion of angiotensin I to angiotensin II by converting enzyme, and degradation of angiotensin II by peptidases.

**Renin.** Renin is a very specific protease that catalyzes the release of the decapetide angiotensin I from angiotensinogen. It is synthesized as a preprohormone that is processed to prorenin, which is inactive, and then to active renin, a glycoprotein consisting of 340 amino acids. Renin in the circulation originates in the kidneys. Enzymes with reninlike activity are present in some extrarenal tissues, but no physiological role for these enzymes has been established. Within the kidney, renin is synthesized and stored in a specialized area of the nephron, the juxtaglomerular apparatus, the major components of which are the afferent and efferent arterioles and the macula densa (Fig. 2). The afferent arteriole and, to a lesser extent, the efferent arteriole contain specialized granular cells called juxtaglomerular cells, which are the site of synthesis, storage, and release of renin. The macula densa is a specialized tubular segment closely associated with the afferent and efferent arterioles. The vascular and tubular components of the juxtaglomerular apparatus, including the juxtaglomerular cells, are innervated by the sympathetic nervous system.

**Control of renin secretion.** The rate at which renin is secreted by the kidney is the primary determinant of activity of the renin-angiotensin system. Renin secretion is controlled by a renal baroreceptor, the macula densa, and the sympathetic nervous system, with short-loop feedback by angiotensin II (4).

**Renal baroreceptor.** The renal baroreceptor monitors renal perfusion pressure and signals an increase in renin release when perfusion pressure falls. The relationship between renin secretion and renal perfusion pressure is shown in Fig. 3. It can be seen that when renal perfusion pressure is above a threshold of ~80 mmHg, renin secretion is low and alterations in pressure cause little change in renin secretion. However, when pressure falls below this threshold, renin secretion is stimulated, increasing in a linear fashion as renal perfusion pressure falls. The receptor is appar-
ently located in the afferent arteriole, and it is possible that the juxtaglomerular cells themselves are sensitive to changes in stretch. As is discussed in Role of Angiotensin in Body Fluid and Blood Pressure Regulation, the renal baroreceptor plays an important role in detecting and minimizing changes in arterial pressure.

Macula densa. The close anatomic relationship between the macula densa and the afferent arteriole suggests that there are functional interactions between these tubular and vascular components of the juxtaglomerular apparatus. It is now known that the macula densa functions as an NaCl sensor and that changes in NaCl concentration in the tubular fluid passing the macula densa cells alter the secretion of renin by the juxtaglomerular cells in the afferent arteriole (6). Chloride is the major signal, with decreased chloride concentration stimulating renin secretion, and vice versa (Fig. 4). These changes are mediated by way of a luminal Na⁺-K⁺-2Cl⁻ cotransporter that is sensitive to changes in luminal Cl⁻ concentration. In sodium-deficient states, decreases in plasma NaCl concentration and glomerular filtration rate (GFR) result in decreased delivery of NaCl to the macula densa, and the resulting activation of the renin-angiotensin system helps to prevent further loss of sodium (see Role of Angiotensin in Body Fluid and Blood Pressure Regulation).

A key question that has stimulated considerable research but that still remains unanswered is how the macula densa communicates with the renin-secreting cells of the afferent arteriole. Substances that have
been proposed as mediators include adenosine, prostaglandins, and, most recently, nitric oxide.

Sympathetic nervous system. Similar to the other vascular and tubular components of the kidney, the juxtaglomerular cells are innervated by sympathetic postganglionic neurons. Renin secretion increases when the renal nerves are stimulated and decreases when the kidneys are denervated (2). The relationship between renin secretion and renal sympathetic nerve activity is shown in Fig. 5. Neural effects on renin secretion are mediated by locally released norepinephrine acting on \( \beta_1 \)-adrenergic receptors. This activates adenyl cyclase and increases the formation of the intracellular messenger cAMP. In some situations, sympathetic stimulation increases renin secretion indirectly by stimulating \( \alpha \)-adrenergic receptors, causing constriction of the afferent arteriole with resultant activation of the renal vascular receptor and decreased delivery of sodium chloride to the macula densa. The reflex increases in sympathetic activity elicited by hemorrhage, standing, and exercise stimulate renin secretion and thus help defend blood pressure in these situations.

Angiotensin. Angiotensin II inhibits renin secretion by increasing blood pressure and by acting directly on the juxtaglomerular cells. The latter action forms the basis of a short-loop negative feedback mechanism controlling renin secretion, a feature common to most endocrine systems. Interruption of this feedback with inhibitors of the renin-angiotensin system (see Drugs That Inhibit Renin Secretion) results in stimulation of renin secretion.

The regulation of renin secretion is summarized in Fig. 6.

**Angiotensinogen.** Angiotensinogen is the circulating protein substrate for renin. It is a glycoprotein with a molecular weight of \(~57,000\) and is synthesized in the liver. The 14 amino acids at the amino terminus of the molecule are shown in Fig. 1. The concentration of angiotensinogen in plasma is less than the Michaelis-Menten constant of the renin-angiotensinogen reaction and is therefore a determinant of the rate of formation of angiotensin.

Angiotensinogen production is increased by glucocorticoids and estrogens. Thus plasma angiotensinogen concentration is increased in patients with Cushing’s syndrome and in patients being treated with glucocorticoids. It is also elevated during pregnancy and in women taking estrogen-containing oral contraceptives. The increased angiotensinogen concentration is thought to contribute to the hypertension that occurs in some of these situations. In this context, it is of interest that there is evidence for a genetic linkage between the angiotensinogen gene and essential hypertension.
Angiotensin I. Angiotensin I contains the peptide sequences necessary for all of the actions of the renin-angiotensin system, but it has little or no biological activity. Instead, it must be converted to angiotensin II by converting enzyme (Fig. 1). Angiotensin I may also be cleaved by plasma or tissue aminopeptidases to form [des-Asp¹]angiotensin I; this in turn is converted to [des-Asp¹]angiotensin II (commonly known as angiotensin III) by converting enzyme.

Converting enzyme. Converting enzyme is a dipeptidyl carboxypeptidase. Its most important substrates are angiotensin I, which it converts to angiotensin II, and bradykinin, which it inactivates. It also cleaves enkephalins and substance P, but the physiological significance of this action has not been established. The action of converting enzyme is restricted by a penultimate prolyl residue, and angiotensin II is therefore not hydrolyzed by converting enzyme. Converting enzyme is located on the luminal surface of vascular endothelial cells throughout the circulation.

Angiotensinase. Angiotensin II is removed rapidly from the circulation, with a half-life of less than one minute. It is metabolized during passage through most vascular beds (an exception being the lungs) by
several peptidases collectively referred to as angiotensinas. Most metabolites of angiotensin II are biologically inactive, but the initial product of aminopeptidase action, [des-Asp^1]angiotensin II, retains considerable biologic activity.

**Actions of Angiotensin II**

Angiotensin II acts at several sites in the body, including vascular smooth muscle, adrenal cortex, kidney, and brain (3). Through these actions, the renin-angiotensin system plays a key role in the regulation of fluid and electrolyte balance and arterial blood pressure (Fig. 6).

**Angiotensin receptors and signaling pathways.** Angiotensin II receptors are located on the plasma membrane of target cells throughout the body. Two distinct receptor subtypes, termed AT_1_ and AT_2_, have been identified (3). Most of the known actions of angiotensin II are mediated by the AT_1_-receptor subtype. This receptor, which belongs to the G protein-coupled receptor superfamily, is a peptide containing ~360 amino acids that spans the cell membrane seven times. Binding of angiotensin II to AT_1_ receptors in vascular smooth muscle results in the phospholipase C-mediated generation of inositol trisphosphate \[\text{Ins}(1,4,5)P_3\] and diacylglycerol (DAG). \[\text{Ins}(1,4,5)P_3\] mobilizes calcium from endoplasmic reticulum, whereas calcium and DAG activate enzymes, including protein kinase C and calcium-calmodulin kinases, that catalyze phosphorylation of proteins. These events result in smooth muscle contraction within seconds. They also initiate slower responses to angiotensin, including vascular growth and ventricular hypertrophy. The function and signal transduction pathways for AT_2_ receptors are still being investigated.

**Blood pressure.** Angiotensin II is a potent pressor agent, considerably more potent than norepinephrine. The pressor response to angiotensin II is rapid in onset (10–15 seconds) and sustained during long-term infusions of the peptide. A large component of the pressor response to intravenous angiotensin II is due to direct contraction of arteriolar smooth muscle. However, angiotensin II also increases blood pressure through actions on the brain and autonomic nervous system. In particular, it acts centrally to increase sympathetic outflow and peripherally to facilitate sympathetic transmission by increasing the release and reducing the reuptake of norepinephrine at adrenergic nerve terminals (5). It also has a less important direct positive inotropic action on the heart. The pressor response to angiotensin is usually accompanied by little or no reflex bradycardia because the peptide acts on the brain to reset the baroreceptor reflex control of heart rate to a higher pressure (5).

**Adrenal cortex.** Angiotensin II acts on the zona glomerulosa of the adrenal cortex to stimulate aldosterone biosynthesis. Aldosterone in turn increases sodium reabsorption in the distal tubule.

**Kidney.** Angiotensin II acts on the kidney to cause renal vasoconstriction, increase proximal tubular sodium reabsorption, and inhibit the secretion of renin.

**Brain.** Angiotensin II acts on the central nervous system to increase blood pressure, stimulate drinking (dipsogenic action), and increase the secretion of vasopressin and ACTH. The physiological significance of these effects is still under investigation.

**Cell growth.** Angiotensin II is mitogenic for vascular and cardiac muscle cells and may contribute to the development of cardiovascular hypertrophy.

**Role of Angiotensin in Body Fluid and Blood Pressure Regulation**

The major physiological function of the renin-angiotensin system is to defend extracellular fluid volume and blood pressure. Consider the response of the renin-angiotensin system to acute loss of blood (Fig. 6). Decreases in blood volume and arterial pressure result in decreased firing of the low- and high-pressure baroreceptors, causing a reflex increase in sympathetic discharge. The increase in renal sympathetic nerve activity, together with decreases in renal artery pressure, GFR, and macula densa NaCl load, causes stimulation of renin secretion. Plasma angiotensin II concentration increases, causing vasoconstriction, stimulation of aldosterone secretion, and increased renal sodium and water reabsorption. These responses combined with increased fluid intake serve
to restore extracellular fluid volume and blood pressure.

Note that the renin-angiotensin system helps to defend blood pressure and blood volume in other situations such as standing and sodium deficiency. With standing, the major stimulus to renin secretion is increased renal sympathetic nerve activity, whereas with sodium deficiency the stimulus is decreased delivery of NaCl to the macula densa.

PATHOPHYSIOLOGY
Up to this point, the emphasis has been on the normal physiology of the renin-angiotensin system. This sets the stage for a brief review of the consequences of the excessive renin secretion that occurs in some forms of hypertension and congestive heart failure. The consequences of excessive renin secretion are readily predictable from the information presented in the preceding section.

Hypertension
The most common form of human hypertension is essential hypertension, the cause(s) of which is still unknown. Other forms of hypertension are caused by endocrine and renal disease. Some of these involve overactivity of the renin-angiotensin system, which is not surprising in view of the potent effect that angiotensin II has on blood pressure.

Overactivity of the renin-angiotensin system is usually caused by increased secretion of renin, with a resultant increase in plasma angiotensin II concentration. Excessive secretion of renin by renin secreting tumors causes severe hypertension. Fortunately, this form of hypertension is both rare and curable. The hypertension associated with narrowing of one or both renal arteries (renovascular or renal hypertension) and several types of renal disease are frequently associated with increased secretion of renin. Finally, renin secretion is increased in a subgroup of patients with essential hypertension.

Overactivity of the renin-angiotensin system can also result from increased production of angiotensinogen. As noted in Angiotensinogen, angiotensinogen production is increased by estrogen therapy, estrogen-containing oral contraceptives, and pregnancy, and this may contribute to the hypertension that sometimes occurs in these situations. Increased production of angiotensinogen may also contribute to the hypertension associated with glucocorticoid therapy or Cushing’s syndrome.

Congestive Heart Failure
The initial pathological event in heart failure is decreased myocardial contractility, which is commonly caused by hypertension and coronary artery disease. Cardiac output and effective blood volume decrease, resulting in increased sympathetic discharge, which in turn stimulates renin secretion. Plasma angiotensin II concentration increases, causing retention of salt and water (Fig. 6) and edema.

FIG. 7.
Two orally active angiotensin II receptor antagonists, losartan and valsartan.
PHARMACOLOGY

The fact that angiotensin contributes to the pathogenesis of several diseases stimulated the development of drugs that inhibit the renin-angiotensin system. This has been an exciting and fruitful area of research, particularly during the past decade, which has seen the development of potent and specific inhibitors of the formation or actions of angiotensin II. Drugs are now available that suppress renin secretion, block angiotensin II receptors, and inhibit the enzymatic action of renin and converting enzyme.

**Drugs That Inhibit Renin Secretion**

- β-Adrenergic blocking drugs such as propranolol decrease renin secretion, and this may contribute to their antihypertensive action. Note, however, that these drugs also reduce blood pressure by actions unrelated to the renin-angiotensin system, including decreased cardiac output. Propranolol and other β-adrenergic blocking drugs suppress renin secretion by blocking renal β-adrenergic receptors (Fig. 6).

**Angiotensin Receptor Antagonists**

Substitution of aliphatic residues such as glycine, alanine, leucine, or threonine for the phenylalanine at the carboxyl terminus of angiotensin II results in the formation of angiotensin receptor antagonists. These drugs block the actions of angiotensin II at the receptor level, thereby reducing the vasoconstrictor and aldosterone-stimulating effects of this peptide. Angiotensin receptor antagonists are being developed for the treatment of hypertension, heart failure, and other disorders associated with the renin-angiotensin system.
formation of competitive antagonists of the action of angiotensin II. Substitution of sarcosine for the amino-terminal aspartic acid prolongs the half-life of the peptides, enhancing their activity. The best-known of these antagonists is \([\text{Sar}_1, \text{Val}_5, \text{Ala}_8]\text{angiotensin II}, or saralasin (\text{Sar}-\text{Arg}-\text{Val}-\text{Tyr}-\text{Val}-\text{His}-\text{Pro}-\text{Ala}).

**Saralasin.** Saralasin possesses some agonist activity and may elicit a pressor response, particularly when circulating angiotensin II levels are low. Saralasin must be administered intravenously, and this severely restricts its use as an antihypertensive agent. However, it can be useful in the detection of renin-dependent hypertension and other hyperreninemic states.

A new class of drugs that block angiotensin II receptors was developed recently (3). An example is losartan, which is a potent and selective antagonist of angiotensin AT\(_1\) receptors (Fig. 7). These drugs interact with amino acids in the transmembrane domains of AT\(_1\) receptors, preventing the binding of angiotensin II. They are orally active and lower blood pressure almost as effectively as converting-enzyme inhibitors but with fewer side effects (see **Converting-Enzyme Inhibitors**). They lower blood pressure in animals with experimental hypertension (Fig. 8; Ref. 7) and in hypertensive patients and are used increasingly in the treatment of hypertension and congestive heart failure.

**Converting-Enzyme Inhibitors**

A nonapeptide inhibitor of converting enzyme was originally isolated from the venom of a South American snake. The synthetic form of this peptide, teprotide, is an effective inhibitor of converting enzyme but is active only when administered intravenously. An important class of orally active converting-enzyme inhibitors, directed against the active site of converting enzyme, is now extensively used. Captopril and enalapril are typical (Fig. 9). Many potent new converting-enzyme inhibitors are now available. It should be noted that converting-enzyme inhibitors not only block the conversion of angiotensin I to angiotensin II but also inhibit the degradation of other peptides, including bradykinin. This latter effect contributes to the antihypertensive action of converting-enzyme inhibitors and may be responsible for side effects such as coughing and angioedema.

### TABLE 1

Comparison of major characteristics of angiotensin II receptor antagonists, converting-enzyme inhibitors, and renin inhibitors

<table>
<thead>
<tr>
<th>Mode of action</th>
<th>Angiotensin II Receptor Antagonists</th>
<th>Converting-Enzyme Inhibitors</th>
<th>Renin Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location of target protein</td>
<td>Block AT(_1) receptors</td>
<td>Inhibit conversion of ANG I to ANG II</td>
<td>Inhibit ANG I formation</td>
</tr>
<tr>
<td>Renin secretion</td>
<td>Increased</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>Plasma renin enzyme activity</td>
<td>Increased</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>AT(_1) receptors</td>
<td>Blocked</td>
<td>Not stimulated (plasma ANG II)</td>
<td>Decreased</td>
</tr>
<tr>
<td>Bradykinin levels</td>
<td>Stimulated (plasma ANG II)*</td>
<td>Not stimulated</td>
<td>Not stimulated (plasma ANG II)</td>
</tr>
<tr>
<td>Main hemodynamic effect</td>
<td>Vasodilation</td>
<td>Vasodilation</td>
<td>Vasodilation</td>
</tr>
<tr>
<td>Renal blood flow</td>
<td>Increased</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>BP in normotensive sodium-replete subjects</td>
<td>Decreased</td>
<td>Decreased</td>
<td>Decreased</td>
</tr>
<tr>
<td>BP in normotensive sodium-depleted subjects</td>
<td>Hypertension, congestive heart failure</td>
<td>None yet</td>
<td>Oral availability too low</td>
</tr>
<tr>
<td>Indications approved in humans</td>
<td>Oral, once daily</td>
<td>Hypertension, congestive heart failure</td>
<td>Oral, once daily</td>
</tr>
<tr>
<td>Mode of administration</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Role of AT\(_2\) receptors is not clear. ANG I or II, angiotensin I or II; BP, blood pressure; ↑, increase; ↓, decrease.
as cough and angioedema. Extensive studies document the value of the converting-enzyme inhibitors in hypertension (Fig. 10; Ref. 1) and congestive heart failure. Indeed, converting-enzyme inhibitors are so effective that they have become one of the cornerstones of the treatment of congestive heart failure. Recent evidence suggests that these drugs may also protect against renal vascular injury in diabetes and other conditions.

**Renin Inhibitors**

Recently, orally active renin inhibitors have been developed (8). These drugs suppress plasma renin activity, thus decreasing plasma angiotensin II concentration. They lower blood pressure in hypertensive patients and have the potential to be as effective as converting-enzyme inhibitors and angiotensin receptor antagonists. However, significant improvement of their oral bioavailability is required.

The major characteristics of angiotensin II receptor antagonists, converting-enzyme inhibitors, and renin inhibitors are compared in Table 1.

**SUMMARY**

The renin-angiotensin system is an important control system that plays a major role in the regulation of fluid and electrolyte balance and of blood pressure. In particular, the system helps defend blood pressure and volume in situations such as hemorrhage, sodium depletion, and changes in posture. Excessive secretion of renin can cause hypertension and exacerbate the abnormalities that occur in other diseases such as congestive heart failure. Several potent orally active drugs that block the formation or actions of angiotensin II are now available and have proven to be very effective in the treatment of hypertension and congestive heart failure.

Address reprint requests to: I. A. Reid, Dept. of Physiology, Box 0444, Univ. of California, San Francisco, CA 94143-0444.

**References**